research use only

Iloperidone 5-HT Receptor inhibitor

Name: Iloperidone
Brand: Selleck Chemicals
SKU: S1483
Availability: InStock
Rating: 5 (3 reviews)

Cat.No.S1483

Iloperidone (HP873) is a dopamine (D2)/serotonin (5-HT2) receptor antagonist, used for the treatment of schizophrenia.

Chemical Structure

Molecular Weight: 426.48

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.99%

99.99

Related Targets	Adrenergic Receptor AChR COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR MAO Beta Amyloid NMDAR iGluR P2 Receptor Trk receptor Serotonin Transporter Notch Norepinephrine Cannabinoid Receptor P-gp CaMK Opioid Receptor BACE Sigma Receptor FAAH Neurokinin Receptor OX Receptor CGRP Receptor CCK receptor
Related Products	Puerarin WAY-100635 Maleate Serotonin (5-HT) HCl BRL-15572 Dihydrochloride SB269970 HCl Ketanserin RS-127445 Azacyclonol Nuciferine Flopropione SB742457 BRL 15572 BRL-54443 Perospirone hydrochloride Alverine Citrate Ramosetron Hydrochloride SB 271046 hydrochloride PRX-08066 Maleic acid Blonanserin PF-04995274 Nafronyl oxalate salt γ-Mangostin YL 0919 Isocorynoxeine 5-Methoxytryptamine VUF 10166 Serotonin Dalasetron Mesylate Hydrate Volinanserin (+)-Isocorynoline

Chemical Information, Storage & Stability

Molecular Weight	426.48	Formula	C₂₄H₂₇FN₂O₄	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	133454-47-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	HP873			Smiles	CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC

Solubility

In vitro
Batch:

DMSO : 27 mg/mL (63.3 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 4 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	2%DMSO 1 40%PEG300 2 ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.600mg/ml (3.75mM)	Taking the 1 mL working solution as an example, add 20 μL of 80 mg/ml clarified DMSO stock solution to 400 μL of PEG 300, mix evenly to clarify it; then continue to add 580 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	5-HT ^[1]
In vitro	Iloperidone displays high affinity (Ki < 10 nM) for norepinephrine alpha(1)-adrenoceptors, dopamine D(3) and serotonin 5-HT(2A) receptors. ^[1] This compound displays higher affinity for the dopamine D3 receptor (Ki = 7.1 nM) than for the dopamine D4 receptor (Ki = 25 nM). It displays high affinity for the 5-HT6 and 5-HT7 receptors (Ki = 42.7 nM and 21.6 nM, respectively), and is found to have higher affinity for the 5-HT2A (Ki = 5.6 nM) than for the 5-HT2C receptor (Ki = 42.8 nM). ^[2] This chemical significantly increases dopa accumulation, an index of dopamine turnover in response to D2 receptor blockade, at doses from 0.3 mg/kg to 10 mg/kg i.p. in the striatum and from 1 mg/kg to 10 mg/kg in the nucleus accumbens. ^[3]
In vivo	Iloperidone exerts behavioral effects in pharmacological rats models of disrupted sensorimotor gating consistent with "atypical" antipsychotics, mediated by antagonism of dopaminergic and noradrenergic receptors. This compound (1 and 3 mg/kg) prevents the PPI-disruptive effects of treatment with 1 mg/kg PCP. It (0.3 mg/kg) prevents cirazoline-induced PPI deficits, independent of its effects on startle magnitude. ^[4] This chemical (10 mg/kg) and Melperone (10 mg/kg) produce an equivalent or a smaller increase in DA release in the nucleus accumbens (NAC) of rats, respectively, compared to the mPFC, whereas none of them increase acetylcholine (ACh) release in the NAC. ^[5]
References	[1] https://pubmed.ncbi.nlm.nih.gov/11750183/ [2] https://pubmed.ncbi.nlm.nih.gov/8997630/ [3] https://pubmed.ncbi.nlm.nih.gov/8768747/ [4] https://pubmed.ncbi.nlm.nih.gov/16762376/ [5] https://pubmed.ncbi.nlm.nih.gov/12445705/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05344365	Withdrawn	Parkinson Disease Psychosis	Vanda Pharmaceuticals	June 2022	Phase 2
NCT04969211	Completed	Healthy	Vanda Pharmaceuticals	June 30 2021	Phase 1
NCT04712734	Completed	Schizophrenia	Vanda Pharmaceuticals	January 13 2021	Phase 1
NCT01495169	Completed	Safety and Tolerability of Iloperidone	Vanda Pharmaceuticals	October 2011	Phase 1
NCT01529294	Completed	Hepatic Impairment	Novartis Pharmaceuticals\|Novartis	August 2010	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):